Subacute metformin treatment reduces inflammation and improves functional outcome following neonatal hypoxia ischemia.

ABSTRACT: Hypoxia-ischemia (HI) injury is a leading cause of neonatal death and long-term disability, and existing treatment options for HI offer only modest benefit. Early intervention with the drug metformin has been shown to promote functional improvement in numerous rodent models of injury and has pleiotropic cellular effects in the brain. We have previously shown that 1 week of metformin treatment initiated 24 ​h after HI in neonatal mice resulted in improved motor and cognitive performance, activation of endogenous neural precursor cells (NPCs), and increased oligodendrogenesis. While promising, a limitation to this work is that immediate pharmacological intervention is not always possible in the clinic. Herein, we investigated whether delaying metformin treatment to begin in the subacute phas

SUBMITTER: Livingston JM 

PROVIDER: S-EPMC8474427 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature